NCT07282652进行中（未招募）1 期
An Investigator-Initiated Study to Evaluate the Safety/Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of RAG-18 in Pediatric Patients With Duchenne Muscular Dystrophy
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
研究概览
简要总结
This is an open-label, single-arm, dose-escalation trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of RAG-18 in pediatric patients with Duchenne Muscular Dystrophy (DMD).
The study will enroll approximately 12 subjects into four cohorts to assess the safety and tolerability of ascending intravenous doses. Secondary objectives include characterizing the pharmacokinetics (PK)/pharmacodynamics (PD) profile and assessing exploratory efficacy through changes in muscle biomarkers, muscle composition, cardiac/pulmonary function, and motor performance. The decision to escalate to the next dose level will be based on a comprehensive safety evaluation of the preceding cohort.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 4 Years 至 15 Years（Child）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •In accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) guidelines and local/national and/or Institutional Review Board (IRB)/Independent Ethics Committee (IEC) requirements, the participant and/or their legal guardian has signed the written informed consent form.
- •Aged 4-15 years old.
- •Male patient with Duchenne Muscular Dystrophy (DMD), able to provide a written diagnosis from a specialist and a verifiable genetic test report.
- •Able to undergo examinations required by the study protocol, such as muscle biopsy, Magnetic Resonance Imaging (MRI), and tests for motor and pulmonary function.
- •Any disease-related concomitant medications must be in compliance with the study's requirements.
排除标准
- •Prior treatment for Duchenne Muscular Dystrophy (DMD), regardless of whether the drug is marketed or not.
- •Body Mass Index (BMI) > 22 kg/m² or body weight ≥ 50 kg.
- •Unable to complete the motor function tests required by the protocol, including: North Star Ambulatory Assessment (NSAA), Time to Stand (TTSTAND), 4-Stair Climb (4SCV), and the 6-Minute Walk Test (6MWT).
- •Cardiac function at screening within the following ranges:
- •Left Ventricular Ejection Fraction (LVEF) < 55% as measured by Cardiac Magnetic Resonance (CMR).
- •QT interval corrected using Fridericia's formula (QTcF) > 450 ms at screening, or has additional risk factors for Torsades de Pointes.
- •Hematology and electrolyte parameters at screening within the following ranges:
- •Platelets < 100,000/μL.
- •Hemoglobin < 12 g/dL.
- •Absolute Neutrophil Count < 1500/μL.
- •Any serum calcium, potassium, sodium, magnesium, or phosphorus levels outside the clinically acceptable range for Duchenne Muscular Dystrophy (DMD) patients.
- •International Normalized Ratio (INR), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Activated Partial Thromboplastin Time (aPTT), or Fibrinogen outside the normal range.
- •History of medical conditions affecting liver function, with abnormal indicators within 28 days prior to the first dose.
- •Presence of severe cardiac, renal, or respiratory dysfunction, or other severe complications.
- •Allergy to the study drug or any of its components, or to Magnetic Resonance Imaging (MRI) contrast agents.
- •Receipt of a live (attenuated) vaccine within 28 days prior to the first dose of the study drug.
- •Use of any other investigational drug, whether for DMD or not, from 28 days prior to the first dose of the study drug until the end of the study.
- •Any reason that, in the investigator's opinion, would prevent the participant from fully participating in and completing the study, including inability to comply with study procedures or treatment, and other relevant medical or mental health conditions.
- •Presence of a severe concomitant condition or disease that, in the investigator's opinion, would place the participant at undue risk or interfere with the study, including but not limited to: known moderate or severe persistent asthma, a history of asthma in the past 2 years, or currently uncontrolled asthma of any classification (Note: participants with currently controlled intermittent asthma or controlled mild persistent asthma are permitted to enroll); requirement for oxygen therapy to maintain adequate blood oxygen saturation; history of Chronic Obstructive Pulmonary Disease (COPD) within 6 months prior to signing the Informed Consent Form (ICF).
- •Participant has an unstable systemic disease as judged by the investigator, including but not limited to severe hepatic, renal, respiratory, or metabolic diseases requiring medication.
- •Any other unspecified reason that, in the investigator's opinion, makes the participant unsuitable for enrollment.
研究组 & 干预措施
RAG-18
Experimental
The study will employ a dose-escalation design, enrolling participants into sequential cohorts for up to four planned dose levels. If the highest planned dose is well-tolerated, a decision to explore further dose escalation may be made based on the overall safety and risk-benefit evaluation.
干预措施: RAG-18 (Drug)
结局指标
主要结局
Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
时间窗: From Baseline up to the end of the study (Day 169)
To evaluate the safety profile of RAG-18 by recording the frequency, nature, and severity of all adverse events and serious adverse events observed during the study. The relationship of these events to the study drug will be assessed.
次要结局
- Maximum Observed Plasma Concentration (Cmax) of RAG-18(Day 1 and Day 85 (assessed at pre-dose, and multiple timepoints up to 168 hours post-dose))
- Time to Maximum Observed Plasma Concentration (Tmax) of RAG-18(Day 1 and Day 85 (PK samples collected at pre-dose and multiple timepoints up to 168 hours post-dose))
- Area Under the Plasma Concentration-Time Curve (AUC) of RAG-18(Day 1 and Day 85 (PK samples collected at pre-dose and multiple timepoints up to 168 hours post-dose))
- Terminal Half-Life (t1/2) of RAG-18(Day 1 and Day 85 (PK samples collected at pre-dose and multiple timepoints up to 168 hours post-dose))
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaDiffuse Large B Cell Lymphoma (DLBCL)NCT07260812TCRx Therapeutics Co.Ltd18
招募中
1 期
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid TumorsColorectal CancerNon-Small Cell Lung CancerNCT07261631Novartis Pharmaceuticals180
进行中（未招募）
2 期
A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)NCT07266090Viatris Pharmaceuticals Co., Ltd.15
招募中
1 期
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid TumorsBreast CancerLung CancerNCT07274852Sichuan Baili Pharmaceutical Co., Ltd.22
招募中
1 期
CYTALUX for Intraoperative Imaging of Patients With Endometrial CancerNCT07278986Abramson Cancer Center at Penn Medicine10